Robert G. Elkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert G. Elkin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Y Zhong
2 shared publicationsYun Ying
Department of Animal Science, The Pennsylvania State University, University Park, State College, PA 16802, USA
2 shared publicationsAhmed S.A. El-Zenary
Department of Animal Science, The Pennsylvania State University, University Park, State College, PA 16802, USA
1 shared publicationAlexandra N. Kukorowski
Department of Animal Science, The Pennsylvania State University, University Park, PA, 16802, USA
1 shared publicationBruce R. Hamaker
Departments of Animal Sciences, Food Science, and Agronomy, Purdue University, West Lafayette, Indiana 47907, and Department of Animal Sciences, University of Illinois, Urbana, Illinois 61801
1 shared publicationCarl M. Parsons
Departments of Animal Sciences, Food Science, and Agronomy, Purdue University, West Lafayette, Indiana 47907, and Department of Animal Sciences, University of Illinois, Urbana, Illinois 61801
1 shared publication
Latest Publications
- Open Access
- 1 September 2020
- Published by Elsevier in Journal of Applied Poultry Research
- Vol. 29 (3) , 730-743
Effect of lowering the amount of dietary linoleic acid on tissue omega-3 fatty acid contents of broilers fed supplemental flaxseed oil from 18 to 35 days of age
- 1 September 2020
- Published by Elsevier in Journal of Applied Poultry Research
- Vol. 29 (3) , 730-743
Open AccessEffect of lowering the amount of dietary linoleic acid on tissue omega-3 fatty acid contents of broilers fed supplemental flaxseed oil from 18 to 35 days of age
Dietary High‐Oleic Acid Soybean Oil Dose Dependently Attenuates Egg Yolk Content of n‐3 Polyunsaturated Fatty Acids in Laying Hens Fed Supplemental Flaxseed Oil
Chickens can hepatically synthesize eicosapentaenoic acid (20:5 n‐3) and docosahexaenoic acid (22:6 n‐3) from α‐linolenic acid (ALA; 18:3 n‐3); however, the process is inefficient and competitively inhibited by dietary linoleic acid (LNA; 18:2 n‐6). In the present study, the influence of dietary high‐oleic acid (OLA; 18:1 n‐9) soybean oil (HOSO) on egg and tissue deposition of ALA and n‐3 polyunsaturated fatty acids (PUFA) synthesized from dietary ALA was investigated in laying hens fed a reduced‐LNA base diet supplemented with high‐ALA flaxseed oil (FLAX). We hypothesized that reducing the dietary level of LNA would promote greater hepatic conversion of ALA to very long‐chain (VLC; >20C) n‐3 PUFA, while supplemental dietary HOSO would simultaneously further enrich eggs with OLA without influencing egg n‐3 PUFA contents. Nine 51‐week‐old hens each were fed 0, 10, 20, or 40 g HOSO/kg diet for 12 weeks. Within each group, supplemental dietary FLAX was increased every 3 weeks from 0 to 10 to 20 to 40 g/kg diet. Compared to controls, dietary FLAX maximally enriched the total n‐3 and VLC n‐3 PUFA contents in egg yolk by 9.4‐fold and 2.2‐fold, respectively, while feeding hens 40 g HOSO/kg diet maximally attenuated the yolk deposition of ALA, VLC n‐3 PUFA, and total n‐3 PUFA by 37, 15, and 32%, respectively. These results suggest that dietary OLA is not neutral with regard to the overall process by which dietary ALA is absorbed, metabolized, and deposited into egg yolk, either intact or in the form of longer‐chain/more unsaturated n‐3 PUFA derivatives.
Dietary High‐Oleic Acid Soybean Oil Dose Dependently Attenuates Egg Yolk Content of n‐3 Polyunsaturated Fatty Acids in Laying Hens Fed Supplemental Flaxseed Oil
Chickens can hepatically synthesize eicosapentaenoic acid (20:5 n‐3) and docosahexaenoic acid (22:6 n‐3) from α‐linolenic acid (ALA; 18:3 n‐3); however, the process is inefficient and competitively inhibited by dietary linoleic acid (LNA; 18:2 n‐6). In the present study, the influence of dietary high‐oleic acid (OLA; 18:1 n‐9) soybean oil (HOSO) on egg and tissue deposition of ALA and n‐3 polyunsaturated fatty acids (PUFA) synthesized from dietary ALA was investigated in laying hens fed a reduced‐LNA base diet supplemented with high‐ALA flaxseed oil (FLAX). We hypothesized that reducing the dietary level of LNA would promote greater hepatic conversion of ALA to very long‐chain (VLC; >20C) n‐3 PUFA, while supplemental dietary HOSO would simultaneously further enrich eggs with OLA without influencing egg n‐3 PUFA contents. Nine 51‐week‐old hens each were fed 0, 10, 20, or 40 g HOSO/kg diet for 12 weeks. Within each group, supplemental dietary FLAX was increased every 3 weeks from 0 to 10 to 20 to 40 g/kg diet. Compared to controls, dietary FLAX maximally enriched the total n‐3 and VLC n‐3 PUFA contents in egg yolk by 9.4‐fold and 2.2‐fold, respectively, while feeding hens 40 g HOSO/kg diet maximally attenuated the yolk deposition of ALA, VLC n‐3 PUFA, and total n‐3 PUFA by 37, 15, and 32%, respectively. These results suggest that dietary OLA is not neutral with regard to the overall process by which dietary ALA is absorbed, metabolized, and deposited into egg yolk, either intact or in the form of longer‐chain/more unsaturated n‐3 PUFA derivatives.
- Open Access
- 1 December 2012
- Published by Elsevier in Animal Reproduction Science
- Vol. 136 (1-2) , 1-13
The restricted ovulator chicken strain: An oviparous vertebrate model of reproductive dysfunction caused by a gene defect affecting an oocyte-specific receptor
- 1 December 2012
- Published by Elsevier in Animal Reproduction Science
- Vol. 136 (1-2) , 1-13
Open AccessThe restricted ovulator chicken strain: An oviparous vertebrate model of reproductive dysfunction caused by a gene defect affecting an oocyte-specific receptor
- Open Access
- 1 January 2009
- Published by Elsevier in Poultry Science
- Vol. 88 (1) , 152-158
Feeding laying hens a bioavailable soy sterol mixture fails to enrich their eggs with phytosterols or elicit egg yolk compositional changes
- 1 January 2009
- Published by Elsevier in Poultry Science
- Vol. 88 (1) , 152-158
Open AccessFeeding laying hens a bioavailable soy sterol mixture fails to enrich their eggs with phytosterols or elicit egg yolk compositional changes
- 1 March 2007
- Published by Taylor & Francis in World's Poultry Science Journal
- Vol. 63 (1) , 5-32
Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging strategies
During the past four decades, research efforts directed toward reducing shell egg cholesterol content have centred on genetic selection or alteration of the laying hens' diet with various nutrients, natural products, non-nutritive factors, or pharmacological agents. However, the vast majority of these experimental approaches elicited only minimal changes (<10%) at best or, as in the case of dietary azasterols and triparanol, resulted in the unacceptable replacement of yolk cholesterol by desmosterol. In contrast, when 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (‘statins’), garlic paste, or pharmacological amounts of copper were orally administered to chickens, yolk cholesterol levels were reduced by up to 46%, 32%, or 34%, respectively. The previous paper in this two-part series provided a justification for low-cholesterol egg production and reviewed cholesterol metabolism in the laying hen, avian embryonic cholesterol needs, and genetic and nutritional approaches to chicken egg cholesterol reduction. The present paper provides a comprehensive overview of the use of non-nutritive dietary factors and select pharmacological compounds as egg cholesterol-lowering agents, and discusses emerging strategies for lowering the cholesterol content of shell eggs. With the recent advances in avian genomics and transgenesis, it is anticipated that the greatest advances in the area of yolk cholesterol reduction will be attained through manipulation of key genes whose protein products mediate intestinal sterol absorption, hepatic cholesterol and lipoprotein synthesis, and/or lipoprotein uptake by growing oocytes. However, the future commercial availability of low-cholesterol eggs produced by transgenic hens ultimately will be influenced by the nature of the regulatory environment for bioengineered foods, public acceptance, and economics.
- 1 March 2007
- Published by Taylor & Francis in World's Poultry Science Journal
- Vol. 63 (1) , 5-32
Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging strategies
During the past four decades, research efforts directed toward reducing shell egg cholesterol content have centred on genetic selection or alteration of the laying hens' diet with various nutrients, natural products, non-nutritive factors, or pharmacological agents. However, the vast majority of these experimental approaches elicited only minimal changes (<10%) at best or, as in the case of dietary azasterols and triparanol, resulted in the unacceptable replacement of yolk cholesterol by desmosterol. In contrast, when 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (‘statins’), garlic paste, or pharmacological amounts of copper were orally administered to chickens, yolk cholesterol levels were reduced by up to 46%, 32%, or 34%, respectively. The previous paper in this two-part series provided a justification for low-cholesterol egg production and reviewed cholesterol metabolism in the laying hen, avian embryonic cholesterol needs, and genetic and nutritional approaches to chicken egg cholesterol reduction. The present paper provides a comprehensive overview of the use of non-nutritive dietary factors and select pharmacological compounds as egg cholesterol-lowering agents, and discusses emerging strategies for lowering the cholesterol content of shell eggs. With the recent advances in avian genomics and transgenesis, it is anticipated that the greatest advances in the area of yolk cholesterol reduction will be attained through manipulation of key genes whose protein products mediate intestinal sterol absorption, hepatic cholesterol and lipoprotein synthesis, and/or lipoprotein uptake by growing oocytes. However, the future commercial availability of low-cholesterol eggs produced by transgenic hens ultimately will be influenced by the nature of the regulatory environment for bioengineered foods, public acceptance, and economics.
- 1 December 2006
- Published by Taylor & Francis in World's Poultry Science Journal
- Vol. 62 (4) , 665-687
Reducing shell egg cholesterol content. I. Overview, genetic approaches, and nutritional strategies
In laying hens, cholesterol is primarily biosynthesized in the liver and incorporated into vitellogenin (VTG) and triglyceride-rich very low density lipoprotein (VLDL) particles, which are secreted into the bloodstream and subsequently taken up by growing oocytes via receptor-mediated endocytosis. VLDL and VTG are then intracellularly transformed into yolk, constituting ∼60% and 24% of yolk dry matter and ∼95% and 5% of yolk cholesterol, respectively. During the past four decades, research efforts directed toward reducing shell egg cholesterol content have centred on genetic selection or alteration of the laying hens' diet with various nutrients, natural products, non-nutritive factors, or pharmacological agents. The present paper will provide a justification for low-cholesterol egg production, primarily in the context of the heterogeneity of response to dietary cholesterol in humans, and will review cholesterol metabolism in the laying hen, avian embryonic cholesterol needs, and genetic and nutritional approaches to chicken egg cholesterol reduction. A subsequent paper will provide a comprehensive overview of the use of non-nutritive dietary factors and select pharmaceuticals as egg cholesterol-lowering agents, and will discuss emerging strategies for lowering the cholesterol content of shell eggs.
- 1 December 2006
- Published by Taylor & Francis in World's Poultry Science Journal
- Vol. 62 (4) , 665-687
Reducing shell egg cholesterol content. I. Overview, genetic approaches, and nutritional strategies
In laying hens, cholesterol is primarily biosynthesized in the liver and incorporated into vitellogenin (VTG) and triglyceride-rich very low density lipoprotein (VLDL) particles, which are secreted into the bloodstream and subsequently taken up by growing oocytes via receptor-mediated endocytosis. VLDL and VTG are then intracellularly transformed into yolk, constituting ∼60% and 24% of yolk dry matter and ∼95% and 5% of yolk cholesterol, respectively. During the past four decades, research efforts directed toward reducing shell egg cholesterol content have centred on genetic selection or alteration of the laying hens' diet with various nutrients, natural products, non-nutritive factors, or pharmacological agents. The present paper will provide a justification for low-cholesterol egg production, primarily in the context of the heterogeneity of response to dietary cholesterol in humans, and will review cholesterol metabolism in the laying hen, avian embryonic cholesterol needs, and genetic and nutritional approaches to chicken egg cholesterol reduction. A subsequent paper will provide a comprehensive overview of the use of non-nutritive dietary factors and select pharmaceuticals as egg cholesterol-lowering agents, and will discuss emerging strategies for lowering the cholesterol content of shell eggs.
- 18 January 2006
- Published by Elsevier in Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology
- Vol. 143 (3) , 319-329
Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens
- 18 January 2006
- Published by Elsevier in Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology
- Vol. 143 (3) , 319-329
Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens
- 29 April 2003
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 51 (11) , 3473-3481
Assessment of Egg Nutrient Compositional Changes and Residue in Eggs, Tissues, and Excreta Following Oral Administration of Atorvastatin to Laying Hens
Laying hens were fed a control diet alone or with 0.06 g of atorvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, per 100 g of diet for 20 days. Compared to controls, egg yolks from treated hens contained greater amounts of amino acids and reduced levels of total fatty acids and cholesterol. In contrast, egg albumen amino acid contents were unaffected by dietary treatments. In a residue study, seven hens each received a single oral dose of ∼20 μCi of [14C]atorvastatin. Approximately 71% of the radioactivity was recovered in the excreta and liver, whereas virtually no radioactivity was detected in kidney, heart, muscle, bile, plasma, or egg albumen at 15 days postdosing. Yolk radioactivity peaked at 4 days postdosing in six of the seven birds and was absent in eggs laid after day 10. Reminiscent of that of certain antibiotic drugs, the atorvastatin egg residue pattern appeared to coincide with the physiological pattern of daily yolk accretion within the ovary. Keywords: Atorvastatin; drug residues; egg nutrient composition; laying hens
- 29 April 2003
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 51 (11) , 3473-3481
Assessment of Egg Nutrient Compositional Changes and Residue in Eggs, Tissues, and Excreta Following Oral Administration of Atorvastatin to Laying Hens
Laying hens were fed a control diet alone or with 0.06 g of atorvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, per 100 g of diet for 20 days. Compared to controls, egg yolks from treated hens contained greater amounts of amino acids and reduced levels of total fatty acids and cholesterol. In contrast, egg albumen amino acid contents were unaffected by dietary treatments. In a residue study, seven hens each received a single oral dose of ∼20 μCi of [14C]atorvastatin. Approximately 71% of the radioactivity was recovered in the excreta and liver, whereas virtually no radioactivity was detected in kidney, heart, muscle, bile, plasma, or egg albumen at 15 days postdosing. Yolk radioactivity peaked at 4 days postdosing in six of the seven birds and was absent in eggs laid after day 10. Reminiscent of that of certain antibiotic drugs, the atorvastatin egg residue pattern appeared to coincide with the physiological pattern of daily yolk accretion within the ovary. Keywords: Atorvastatin; drug residues; egg nutrient composition; laying hens
- Open Access
- 1 April 2003
- Published by Elsevier in Poultry Science
- Vol. 82 (4) , 517-525
Validation of a modified PCR-based method for identifying mutant restricted ovulator chickens: substantiation of genotypic classification by phenotypic traits
Upon photostimulation, restricted ovulator (RO) female chickens exhibit endogenous hyperlipidemia, develop atherosclerotic lesions, and generally fail to lay eggs. This phenotype results from a point mutation in the gene specifying the very low density lipoprotein receptor (VLDLR), whose protein product normally mediates the massive oocytic uptake of egg yolk precursors from the circulation. Taking advantage of the single base change in the mutant VLDLR allele, a PCR-based method for the rapid identification of RO chickens was developed at the Biocenter and University of Vienna, Austria. However, this procedure was incompletely validated because phenotypic data were not obtained and conventional progeny testing of sons and grandsons was not performed. Here, the assay validation was completed by providing plasma lipid concentrations, plasma very low density lipoprotein particle sizes, or egg production records of PCR-genotyped females and their brothers and sires to demonstrate that each bird's phenotypic traits substantiated their genotypic classification. Moreover, several methodological modifications resulted in improved chemical safety, speed, and cost of preparing and analyzing genomic DNA from chicken erythrocytes. Because the ovaries of mutant RO females generally contain numerous vitellogenic follicles in the absence of a functional oocyte plasma membrane VLDLR, the existence of an alternate system for the oocytic uptake of plasma very low density lipoprotein and vitellogenin is suggested, whereas a physiological explanation as to why some, but not all, mutant RO hens are able to ovulate and lay eggs is lacking.
- 1 April 2003
- Published by Elsevier in Poultry Science
- Vol. 82 (4) , 517-525
Open AccessValidation of a modified PCR-based method for identifying mutant restricted ovulator chickens: substantiation of genotypic classification by phenotypic traits
Upon photostimulation, restricted ovulator (RO) female chickens exhibit endogenous hyperlipidemia, develop atherosclerotic lesions, and generally fail to lay eggs. This phenotype results from a point mutation in the gene specifying the very low density lipoprotein receptor (VLDLR), whose protein product normally mediates the massive oocytic uptake of egg yolk precursors from the circulation. Taking advantage of the single base change in the mutant VLDLR allele, a PCR-based method for the rapid identification of RO chickens was developed at the Biocenter and University of Vienna, Austria. However, this procedure was incompletely validated because phenotypic data were not obtained and conventional progeny testing of sons and grandsons was not performed. Here, the assay validation was completed by providing plasma lipid concentrations, plasma very low density lipoprotein particle sizes, or egg production records of PCR-genotyped females and their brothers and sires to demonstrate that each bird's phenotypic traits substantiated their genotypic classification. Moreover, several methodological modifications resulted in improved chemical safety, speed, and cost of preparing and analyzing genomic DNA from chicken erythrocytes. Because the ovaries of mutant RO females generally contain numerous vitellogenic follicles in the absence of a functional oocyte plasma membrane VLDLR, the existence of an alternate system for the oocytic uptake of plasma very low density lipoprotein and vitellogenin is suggested, whereas a physiological explanation as to why some, but not all, mutant RO hens are able to ovulate and lay eggs is lacking.
- Open Access
- 1 September 2002
- Published by Elsevier in Poultry Science
- Vol. 81 (9) , 1280-1282
Assessment of reproductive function in mutant restricted ovulator carrier roosters
Two splice variant forms of the chicken very low density lipoprotein receptor (VLDLR) have recently been shown to exist in both male and female chicken gonads. The longer form, containing an O-linked sugar domain, is produced in the somatic cells of the testes and ovaries, whereas the shorter form, which lacks this domain, is expressed in the male and female germ cells. The latter is essential for female reproduction, because a naturally occurring point mutation in the gene encoding the short form of the VLDLR causes its functional absence, resulting in atherosclerosis and a general failure to lay eggs. Thus, the term restricted ovulator (RO) was originally coined to describe females with the mutant gene. In contrast, the roles of the VLDLR gene products in male reproduction have yet to be defined, because only heterozygous RO roosters, which have a mutant allele of the VLDLR gene (short form) on one of their two Z (sex) chromosomes, can be obtained. However, the question of whether two normal alleles of the VLDLR gene are needed for optimal male reproductive performance can be addressed. Here, the reproductive abilities of heterozygous RO roosters were compared to their wild-type siblings. The RO roosters were found to be phenotypically normal, suggesting that only one normal allele for the VLDLR gene is needed for optimal male reproductive performance. Alternately, it is also possible that the one normal allele compensated for the presence of the mutant one in terms of VLDLR gene product production (i.e., a dosage compensation).
- 1 September 2002
- Published by Elsevier in Poultry Science
- Vol. 81 (9) , 1280-1282
Open AccessAssessment of reproductive function in mutant restricted ovulator carrier roosters
Two splice variant forms of the chicken very low density lipoprotein receptor (VLDLR) have recently been shown to exist in both male and female chicken gonads. The longer form, containing an O-linked sugar domain, is produced in the somatic cells of the testes and ovaries, whereas the shorter form, which lacks this domain, is expressed in the male and female germ cells. The latter is essential for female reproduction, because a naturally occurring point mutation in the gene encoding the short form of the VLDLR causes its functional absence, resulting in atherosclerosis and a general failure to lay eggs. Thus, the term restricted ovulator (RO) was originally coined to describe females with the mutant gene. In contrast, the roles of the VLDLR gene products in male reproduction have yet to be defined, because only heterozygous RO roosters, which have a mutant allele of the VLDLR gene (short form) on one of their two Z (sex) chromosomes, can be obtained. However, the question of whether two normal alleles of the VLDLR gene are needed for optimal male reproductive performance can be addressed. Here, the reproductive abilities of heterozygous RO roosters were compared to their wild-type siblings. The RO roosters were found to be phenotypically normal, suggesting that only one normal allele for the VLDLR gene is needed for optimal male reproductive performance. Alternately, it is also possible that the one normal allele compensated for the presence of the mutant one in terms of VLDLR gene product production (i.e., a dosage compensation).